The Medicare GLP-1 Bridge, Explained ($50/Month Wegovy & Zepbound)

What is the Medicare GLP-1 Bridge?

The Bridge is a temporary CMS pilot operating under demonstration authority. It does not permanently rewrite Medicare drug law, and the existing Part D exclusion for weight-loss drugs remains unchanged.

The pilot began July 1, 2026 and is scheduled to end December 31, 2027. For people who meet every rule, it provides a flat $50 monthly copay for one of a limited number of covered products. Income does not change that amount. Sources: CMS; Medicare.gov: weight-loss drugs

Exact Medicare GLP-1 Bridge eligibility rules

You must satisfy all of the following. Meeting only the age or BMI requirement is not enough.

1. You must have eligible Part D coverage.
   Private Fee-for-Service (PFFS), cost plans and Programs of All-Inclusive Care for the Elderly (PACE) do not qualify for this pilot.
2. You must not already be receiving a GLP-1 through Part D.
3. You must not have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver.
   According to the pilot rules, those conditions go through normal Part D coverage rather than the Bridge.
4. You must be at least 18 years old.
5. You must fit at least one of the following BMI and health-history groups:
   • BMI of 35 or higher; or
   • BMI of 30 or higher plus heart failure, uncontrolled hypertension, or chronic kidney disease stage 3a or higher; or
   • BMI of 27 or higher plus prediabetes, a prior heart attack, a prior stroke, or peripheral artery disease.

Sources: CMS Medicare GLP-1 Bridge page; Medicare Fact Sheet, Product No. 12234

Which drugs and formulations does the Bridge cover?

The covered list is product-specific. A drug name alone is not always enough: the Zepbound delivery format matters.

Sources: CMS Medicare GLP-1 Bridge page; Medicare Fact Sheet, Product No. 12234

How to talk to your prescriber

Your prescriber decides what treatment is medically appropriate. Your job as a patient is to make sure the conversation uses the Bridge’s exact rules instead of relying on the general statement that “Medicare does not cover weight-loss drugs.”

You can bring this checklist to the appointment:

• Confirm that you are age 18 or older.
• Confirm your current BMI.
• Review whether you have one of the listed conditions that goes with the BMI 30 or BMI 27 pathways.
• Discuss whether you have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver, because the Bridge directs those conditions to normal Part D coverage.
• Confirm whether you are already receiving a GLP-1 through Part D.
• Show the prescriber the exact covered-product list, including the rule that only the Zepbound KwikPen is covered under the pilot.
• Ask whether a covered Bridge product is medically appropriate for you.

What if you do not qualify for the Bridge?

1. Check whether the Bridge is the wrong coverage route

If you have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver, the pilot says those conditions go through normal Part D, not the Bridge. That does not mean the Bridge should make an exception; it means you and your prescriber should discuss the ordinary Part D coverage route. Sources: CMS; Medicare.gov

2. Separate true ineligibility from an incorrect denial

An appeal can challenge a plan’s decision or an incorrect application of the rules. It does not change the Bridge’s eligibility rules. If, for example, you do not meet one of the BMI pathways, an appeal cannot rewrite the pilot’s threshold.

If you believe the decision is wrong, compare the denial with the exact criteria above. Check the drug formulation, your Part D arrangement, whether the decision treated a qualifying condition correctly, and whether the request was evaluated under the Bridge or normal Part D.

3. Consider self-pay pricing carefully

Manufacturer self-pay programs exist, but they are substantially more than the Bridge’s $50 monthly copay. Current verified prices are listed below. Prices and program terms can change, so check the manufacturer’s terms before paying.

4. Be cautious with compounded products

Compounded GLP-1s have not been broadly legal since the FDA shortages were resolved in December 2024 and February 2025. A narrow, patient-specific 503A exception remains. In April 2026, the FDA proposed tightening the rules further. Source: U.S. Food and Drug Administration

If coverage is denied: the Part D appeal path

For a Part D drug request, the initial decision is called a coverage determination. The standard decision timeframe is 72 hours; an expedited determination is 24 hours.

1. Coverage determination: the initial Part D decision.
2. Redetermination: the first appeal, decided by the plan.
3. Reconsideration: the next level, handled by an independent review entity.

Medicare beneficiaries can get free, one-to-one help from the State Health Insurance Assistance Program at SHIPhelp.org.

Appeals are often overlooked

KFF’s 2024 data found that 80.7% of appealed Medicare Advantage prior-authorization denials succeeded; that analysis was published in January 2026. KFF also found that 34% of appealed ACA Marketplace claim denials were overturned. Fewer than 1% of denials were appealed in the cited analyses. Source: KFF

Verified Wegovy and Zepbound self-pay prices

If the Bridge and insurance coverage are unavailable, these were the verified manufacturer self-pay terms as of July 19, 2026.

Sources: NovoCare; LillyDirect

Savings cards are not available to Medicare beneficiaries

Manufacturer savings cards are for eligible people with commercial insurance only. They cannot be used with Medicare or Medicaid because of federal anti-kickback restrictions.

• Wegovy savings card: as low as $25 per month, with a maximum $100 monthly benefit.
• Zepbound savings card: as low as $25 per fill of up to three months; the card expires December 31, 2026.

Sources: NovoCare; Zepbound savings information

Frequently asked questions